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false positive rates in randomized controlled 
trials? A snap review
Theophile Bigirumurame*  and Adetayo S. Kasim
Abstract 
Objective: The use of minimum clinically important difference in the hypothesis formulation for superiority trials is 
similar in principle to the concept of non-inferiority or equivalence trial. However, most clinical trials are analysed test-
ing zero clinical difference. Since the minimum clinically important difference is pre-defined for power calculation, it is 
important to incorporate it in both the hypothesis testing and the interpretation of findings from clinical trials.
Results: We reviewed a set of 50 publications (25 with binary outcome, and 25 with survival time outcome). 20% of 
the 50 published trials that were statistically significant, were also clinically significant based on the minimum clini-
cally important risk differences (or hazard ratio) used for their power calculations. This snap review seems to suggest 
that most published trials with statistically significant results were less likely to be clinically significant, which may 
partly explain the high false positive findings associated with findings from superiority trials. Furthermore, none of the 
reviewed publications explicitly used minimum clinically important difference in the interpretation of their findings. 
However, a systematic review is needed to critically appraise the impact of the current practice on false positive rate in 
published trials with significant findings.
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Introduction
A lot has been said over the years about the limitation 
of null hypothesis significance testing, particularly with 
respect to false positive rates among the published find-
ings [1]. What is also clear, is that the main problem is 
how the null hypothesis significance testing is used rather 
than the statistical approach itself [2]. One cause for con-
cern is a mismatch between hypothesis formulation for 
power calculation and the hypothesis assumed for ana-
lysing trial data. Typically, sample size calculation for 
randomised controlled trials is based on a minimum clin-
ically important difference (MCID) that should support 
both statistical significance and clinical findings from 
the trial. The objective of this snap review is to investi-
gate how often the pre-specified minimum clinically 
important difference is used in the interpretation of find-
ings from a clinical trial. We also aim to show that most 
published trials with statistical significant results are not 
necessarily clinically significant, which we believe may 
partly explain the high false positive rate associated with 
findings from superiority trials.
Main text
Let δ be the MCID, then a 2-sided hypothesis for power 
calculation taking into account both statistical and clini-
cal significance can be formulated as:
where: µ1 and µ2 are the expected means for the control 
(or placebo) and the active groups, respectively (if we 
consider a normally distributed outcome).
The use of MCID in the hypothesis formulation for 
superiority trials is similar in principle to the concept of 
non-inferiority or equivalence trials. However most clini-
cal trials are analysed assuming zero clinical difference 
based on the hypothesis:
H0 : −δ ≤ µ2 − µ1 ≤ δ,
H1 : µ2 − µ1 ≤ −δ or µ2 − µ1 ≥ δ.
Open Access
BMC Research Notes
*Correspondence:  theophile.bigirumurame@durham.ac.uk 
Durham University, University boulevard, Stockton-on-Tees TS17 6BH, UK
Page 2 of 4Bigirumurame and Kasim  BMC Res Notes  (2017) 10:775 
The clinical relevance of the findings is left to the quali-
tative judgement of clinicians and researchers. Since 
MCID has been pre-defined for power calculation, it is 
natural to incorporate this value in testing and interpret-
ing results from clinical trials. A framework that was 
proposed by [3] and [4] is using confidence interval as 
illustrated in Fig. 1.
We performed our snap review by searching all pub-
lished parallel group randomised trials using the search 
terms “randomised controlled trials”, “randomized con-
trolled trials”, “phase 3”, “superiority trials” for articles 
published in New England Journal of Medicine and The 
Lancet between 2004 and March 2017. We have only con-
sidered the two journals in our snap review because of 
the high quality of their publications, likelihood to report 
relevant information on MCID and the limited resources 
on our side to do this snap review. We acknowledge 
that restricting our review to only the two journals may 
imply that our conclusion may be biased and may not be 
broadly applicable to all published trials. However, we 
believe the objective of this snap review remains valid 
and timely to warrant a future systematic review of this 
topic. We screened abstracts and result sections of the 
papers to identify those published with significant results 
(P values < 0.05). We excluded articles which did not 
report minimum clinically important difference used for 
sample size calculation. For dichotomous outcomes, we 
noted that different statistics were used to estimate treat-
ment effects (odds ratio, relative risk, relative risk reduc-
tion, risk difference). We expressed MCID and treatment 
H0 : µ2 − µ1 = 0,
H1 : µ2 − µ1 �= 0.
effects as risk difference (proportion in the active treat-
ment group minus the proportion in the control group). 
Confidence intervals were computed using the normal 
approximation. For time to event outcomes, we only 
selected publications in which the MCID and treatment 
effects were expressed as hazard ratio (HR). Since there 
were very few publications with continuous outcomes, 
we focused only on dichotomous and survival outcomes.
Selected publications were then grouped into two cat-
egories based on the primary endpoint types (survival or 
binary endpoint). Figure 2 presents selected publications 
for binary endpoint group.
The vertical dashed line shows the zero difference. 
As expected, the estimated risk differences ± 95% con-
fidence interval (C.I.) lie on either side of the zero line 
depending on whether the goal of the trial is to establish 
positive or negative impact of the interventions (improve-
ment in response rate or reduction in risk rate). In Fig. 2, 
4 of the 25 (16%) publications reported risk differences 
(RD) which were both statistically and clinically signifi-
cant with estimated RD and confidence intervals bounds 
greater than their pre-specified MCID (in absolute value). 
2 of the 25 (8%) publications reported RD which were 
statistically significant but not clinically significant with 
estimated RD and confidence intervals bounds smaller 
than their pre-specified MCID (in absolute value). The 
remaining trials (76%) reported statistically significant 
but not necessarily clinically significant RD since their 
pre-specified MCID were within the bounds of their esti-
mated confidence intervals. For the survival endpoint, 
selected publications are shown in Fig. 3.
6 of the 25 (24%) publications reported HR which 
were both statistically and clinically significant. 1 of the 
Fig. 1 Statistical and clinical significance evaluated using confidence intervals
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25 (4%) publications reported HR which was statistically 
significant but not clinically significant. The remaining 
72% of publications reported HR which were statistically 
significant but not necessarily clinically significant. Com-
bining results from the two groups, it can be shown that 
only 10 of the 50 (20%) publications reported estimates 
which were both statistically and clinically significant. 6% 
of the published results were statistically significant but 
not clinically significant. The remaining 74% of publica-
tions were statistically significant but not necessary clini-
cally significant. Comparable results were reported by [5] 
in their investigation of publicly funded trials. Further-
more, none of the reviewed publications explicitly used 
MCID in the interpretation of their findings.
Limitations
Our findings support the need to improve the way 
hypothesis testing is conducted for superiority trials. In 
most superiority trials, the MCID is only used in the sam-
ple size calculation. This approach should be improved by 
taking into account all the information used in sample 
size calculation during the analysis and interpretation of 
the trial data. To improve reliability of published results, 
investigators should do more to report all the necessary 
information used for sample size calculation.
This snap review seems to suggest that most published 
trials with statistically significant results were less likely 
to be clinically significant, which may partly explain the 
high false positive findings associated with findings from 
superiority trials. However, a systematic review is needed 
to critically appraise the impact of the current practice 
on false positive rates in published trials with signifi-
cant findings. In addition to a systematic a review, our 
future research will investigate the degree of association 
between clinical significance and false positive findings 
by assessing whether findings that are both statistically 
and clinically significant have smaller false positive rate. 
We would also like to investigate whether Bayesian local 
false discovery rate can predict false positive findings in 
published trials. This snap review assumed that the mini-
mum clinically important difference has been correctly 
specified, guidance on how to best determine the most 
plausible minimum clinically important difference for a 
trial is provided by  DELTA2 initiative [6].
The review of publications from only two journals is 
a major limitation because our conclusion may not be 
broadly applicable to all published journals. We chose 
these two journals because of the high quality of their 
publications and the likelihood to report the relevant 
information on sample size calculation, particularly 
the assumed MCID. Another limitation is that the snap 
review and our conclusions assumed that the sample 
size calculation have correctly been determined and that 
the value specified as MCID is correct. However, deter-
mining appropriate MCID is not straight forward and 
 DELTA2 proposed different ways to determine MCID. 
Lastly, this snap review did not follow a rigorous sys-
tematic review approach and the criteria used to select 
the publications may suffer from selection bias. In spite 
of these limitations, we believe that this snap review is 
informative given the ongoing concerns about signifi-
cance hypothesis testing and lack of reproducibility of 
published findings from clinical trials.
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